PharmaShots | Incisive News in 3 Shots

Subscribe Now

Moderate to Severe Chronic

UCB Reports Results of Bimekizumab in P-III BE VIVID Study to Treat Moderate to Severe Chronic Plaque Psoriasis

UCB Reports Results of Bimekizumab in P-III BE VIVID Study to Treat Moderate to Severe Chronic Plaque Psoriasis

October 17, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us